Background
Arrhythmogenic right ventricular cardiomyopathy (ARVC) (MIM #107970) is a myocardial disease in which myocardium of the right ventricular free wall is partially or almost entirely replaced by fibro-fatty tissue [
1], leading to structural and functional abnormalities of the right ventricle, electrocardiographic depolarization/repolarization changes and arrhythmias of right ventricular origin [
2]. Clinical symptoms are manifested in the early adulthood.
The disease is transmitted as an autosomal dominant trait with reduced penetrance. Although pathogenic mutations underlying ARVC were detected in
RyR2 (cardiac ryanodine receptor) [
3] and in
TGFβ3 (transforming growth factor-β3) [
4] genes, finding mutations in genes encoding desmosomal proteins, namely Desmoplakin (
DSP), Plakophilin-2 (
PKP2) and Desmoglein-2 (
DSG2) [
5‐
7] led to current idea that ARVC is due to desmosomal dysfunction [
8]. This was further strengthened by two recent studies that reported mutations in the desmosomal desmocollin-2 (
DSC2) gene as the cause of ARVC [
9,
10]. Actually, also the autosomal recessive form of ARVC, known as Naxos syndrome, associated with palmoplantar keratoderma and peculiar woolly hairs (MIM #601214) is due to mutation in the desmosomal protein Plakoglobin (JUP) [
11]. Moreover, intercalated discs ultrastructural abnormalities consisting of decreased desmosome number and intercellular gap widening were observed in ARVC biopsy samples [
12].
Desmosomes anchor stress-bearing intermediate filaments at sites of strong intercellular adhesion; the resulting scaffold plays a key role in providing mechanical integrity of tissues which undergo high mechanical stress, such as epidermis and heart [
13]. Desmosomes include proteins from at least three distinct gene families: cadherins, armadillo proteins and plakins [
14]. Desmosomal cadherins include DSGs and DSCs; members of both subfamilies are single-pass transmembrane glycoproteins, mediating Ca
2+-dependent cell-cell adhesion.
We report here two novel mutations of the DSC2 gene detected in patients affected with ARVC and their functional characterization.
Methods
Clinical evaluation
Clinical diagnosis of ARVC was based on major and minor criteria established by the European Society of Cardiology/International Society and Federation of Cardiology Task Force [
15]. The study involved a cohort of 54 patients of Italian descent. Each patient underwent cardiological examination. The clinical study protocol included 12-lead electrocardiogram (ECG), signal-averaged ECG (SAECG), 24-hour Holter ECG, and 2-dimensional echocardiography, performed according to previously reported methods [
2]. All clinical investigations and blood sampling for DNA analysis were performed under informed consent, according to the pertinent Italian legislation and in compliance with Helsinki declaration.
Mutation screening
Fifty-four Italian probands (33 males and 21 females), which proved negative for mutations of DSP, PKP2, DSG2 and TGFβ3 genes, were screened for DSC2 mutations by denaturing high-performance liquid chromatography (DHPLC) and direct sequencing.
Primers flanking each exon of the human
DSC2 gene were designed by PRIMER3. PCR amplifications were performed in a final volume of 25 μl, containing 50 ng of genomic DNA, 400 nmol/l of each primer (Sigma Genosys), 100 μmol/l of each dNTP, 1.5 μmol/l MgCl
2, and 0.8 U of Taq DNA Polymerase (TaqGold, Applied Biosystems). PCR primers and DHPLC conditions are reported in Table
1. DHPLC analysis was performed with the use of WAVE Nucleic Acid Fragment Analysis System 3500 HT (Transgenomic Ltd NE, USA). Samples showing a change in DHPLC pattern were directly sequenced.
DSC2 sequences were compared to reference sequence NM_024422.
Table 1
PCR primers and conditions for DHPLC analysis of DSC2 gene
1+5'UTR | 708 | Direct sequencing | TCAGACCTCGCTCTGTAATTGA | TATCCCCGTTCCCCTAGTTT |
2 | 199 | Direct sequencing | ACACATTAAAGTTTTCTTTTTAT | GGCGTATATGTACCACAGCA |
3 | 400 | 54,8/55,4 | CCCCACGTGCATACATTACT | TGGTTTTCATTCGTCTTTAAGC |
4 | 269 | 55,6/58.5 | CCCCTACCCAGCTAATCCTC | GGAAACTATAGACTCCCACAGCA |
5 | 332 | 56,5/57,2 | TGAAAGCTCTGCTGAAATAAAGA | GGAGTAGCCAGAGCATTGGT |
6 | 266 | 54.7 | GCCAAAATGAATTTGAAGCATAC | TTGAAACACAGTTAATTTGCCATA |
7 | 384 | 55/58/59,5 | CATAGAACATGTGAATGTTTTGGA | CAAAACCAGCATACTCCAAGG |
8 | 252 | 54,3/55.6 | GTTGGTGCTTTCCCCCAATA | AGGCCAGAGATGTGCATATTA |
9 | 324 | 52.2/53.5/55.3 | CATCGTGTTCAATTTTTGTGA | CCTTTCTTTCCATTAAATTCTAGC |
10 | 374 | 56,5/57,9 | ACTCGTTAGCATTGCCAAAT | TAACGTAACAAAATAAGCTA |
11 | 375 | 51,7/56 | CAAGAAGTAGCAGTGGCATAAGG | AACAGAGTGCATGTATCCAGCTT |
12 | 345 | 57/58/59 | GTGTTCAGTGCATACTTTTGTGG | GCAGACATCCTGATGTTGAAAA |
13 | 356 | 57,2/58 | TGTTCAGAAGAAATCAGTGACA | GTGTCTTGAAAGTTACTTTAAAGG |
14 | 263 | 57.7 | GATTTATGTGTGTATTAACCATTG | CGCATTATAAGCGAATTCATCC |
15 | a 194 | 56.2/60.6/61.8 | CATAATTTTGTGTTCCTCTCTGT | AGGATTCCGAGGTCTGGTGT |
| b 332 | 61/61,4/62,2 | GGCTTCACAACCCAAACTGT | TGAAAATTATAGTCAGAATCCAGT |
15' | 226 | 53,7/55,2 | GCCACATGCGTGACTTTTAG | ACTTTCTGCCAAGGGGAAAA |
16 | 397 | 56,3/56,8 | CAATGAAAGGTAAATCAAAGCAA | AAAAACCCCCACAAATAGCA |
A control group of 250 healthy and unrelated subjects (500 chromosomes) from Italian population was used for assessing possible polymorphism of detected DNA variants. All controls were matched to the probands by ancestry.
Presence of the missense mutations p.E102K and p.I345T was confirmed by restriction digest of PCR amplicons with TspR1 restriction enzyme (NEW ENGLAND BioLabs).
Cell cultures
Cardiac ventricular myocytes from one to three days old Crl:(WI)BR-Wistar rats (Charles River Laboratories, Wilmington, MA) were prepared as previously described [
16]. All animal procedures were followed according to institutional guidelines.
HL-1 cardiac myocytes were maintained as previously reported [
17].
Plasmid construction
The cDNA of human DSC2a was kindly provided by Dr W.W. Franke (Heidelberg, Germany) and human DSC2a full-length coding sequence (GenBank NM_024422) was PCR-amplified with the following primers: DSC2a-clonF: ATTATGGAGGCAGCCCGCCC; DSC2a-clonR: GTCTCTTCATGCATGCTTCTGCTAG. The resulting fragment was cloned into pcDNA3.1/CT-GFP-topo eukaryotic expression vector (Invitrogen) which contains cDNA coding for green fluorescent protein (GFP), and verified by sequence analysis.
Site directed mutagenesis
Site-directed mutagenesis was performed on DSC2a-pcDNA3.1/CT-GFP, in order to reproduce two DSC2 naturally occurring mutations: p.E102K (EF017811), and p.I345T (EF017812). We used the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene) and the following mutagenic primers: E102K-F: TACCATATTACTTTCCAACACTAAGAACCAAGAAAAGAAGAAAAT; E102K-R: ATTTTCTTCTTTTCTTGGTTCTTAGTGTTGGAAAGTAATATGGTA; I345T-F: CAACTTCAACTTGTATCATTAACACTGATGATGTAAATGACCACTTGC; I345T-R: GCAAGTGGTCATTTACATCATCAGTGTTAATGATACAAGTTGAAGTTG. All clones were verified by sequence analysis.
Transfection of neonatal rat cardiomyocytes and HL-1 cells with wild-type and mutant DSC2a-pcDNA3.1/CT
After 1 day in culture, cardiomyocytes were transfected with 3 μg of plasmid DNA per well and 8 μl of transfection reagent (transfectin lipid reagent Biorad). After 24 hours of transfection, cells were fixed for 20 minutes with 4% paraformaldehyde in phosphate-buffered saline, and then permeabilized with 0.1% Triton X-100 for 10 minutes. HL-1 cells were transfected with 0.8 μg of plasmid DNA per plate, 6.4 μl of enhancer reagent, and 8 μl of effectene reagent (Qiagen). At 48 hours post-transfection, HL-1 cells were fixed with cold methanol/acetone (1:1) for 20 minutes at -20°C. Each set of subsequent experiments was performed in triplicate in 24 mm glass coverslips and was repeated 3 times.
Immunostaining and confocal imaging on neonatal rat cardiomyocytes and HL-1 cells
Neonatal rat cardiomyocytes were stained with anti-alpha actinin antibody (Sigma) for two hours at room temperature, washed three times with PBS and incubated with Alexa fluor 543-conjugated antimouse antibody (Molecular Probes, Eugene, Ore). HL-1 cells were incubated with the murine mAb (clone DG3.10) against bovine dsg (PROGEN, Heidelberg, Germany), which reacts with a carboxy terminal epitope of desmoglein for 30 min at 37°C, washed three times with PBS, and incubated with TRITC conjugated antibodies (DAKO).
Slides were inspected and photographed using a Radiance 2000 confocal microscope (BioRad) with a 60× oil objective.
Discussion
In the present study, we identified two mutations in
DSC2 gene associated with ARVC, a genetically determined heart muscle disease characterized by structural, electrical, and pathological abnormalities of the right ventricle. Thus far, only 3
DSC2 mutations have been reported in ARVC patients [
9,
10]. On the basis of present data and of those previously reported [
9,
10], DSC2 mutations account for only a small percentage of ARVC probands.
Desmosomal cadherins, DSGs and DSCs, mediate cell-cell adhesion by interacting laterally and transcellularly with each other and by recruiting cytoplasmic plaque proteins which facilitate attachment of intermediate filaments. In particular, DSCs dimerise laterally via homophilic and heterophilic interactions at the cell surface and also make head-to-head contacts across the intercellular gap to form the so-called "adhesive zipper" [
19]. Moreover, it has been suggested that DSC2 expressed at cell surface might act as nucleation centres for subsequent assembly of functional desmosomes [
20].
Desmocollins bind desmosomal cadherins through their extracellular domains, while the cytoplasmic domains have binding sites for desmosomal plaque proteins. DSCs occur as "a" and "b" splice variants, with the "a" variant having a slightly longer cytoplasmic domain. It has been shown that the "a" variant can support desmosomal assembly [
21], but there is no known function for the "b" form. In humans, there are three desmocollin isoforms (DSC1–3); DSC2 is almost ubiquitous in human tissues, but it is the only desmocollin isoform expressed in cardiac tissue [
22].
DSC2 is a membrane glycoprotein composed of four highly conserved extracellular subdomains (EC1–4), a more variable extracellular anchor domain (EA), a single transmembrane domain (TM), an intracellular anchor domain (IA) and a cytoplasmic region that can show two different isoforms.
Cadherins are synthesized as inactive precursor proteins containing a prosequence followed by the cadherin domains. The N-terminal prosequence is proteolytically cleaved off in the late Golgi and the mature cadherin is then transported to the plasma membrane. Proteolytic removal of the prosequence results in structural rearrangements within EC1 domain with the activation of adhesive properties [
23]. Mutation p.E102K alters a conserved amino acid located in the propeptide region.
Mutation p.I345T is located in the EC2 domain, which forms, together with EC1, the "minimal essential unit" to mediate cell adhesion, through
cis and
trans interactions among desmosomal cadherins [
24].
In vitro functional studies on neonatal rat cardiomyocytes and on HL-1 cells demonstrate that the two missense mutations in the N-terminal domain affect the normal localisation of DSC2. As previously reported, the wild-type DSC2a-GFP fusion protein was efficiently incorporated into desmosomes and did not exert dominant-negative effect when overexpressed [
25]. A lower amount of GFP signal was detected in the cytoplasm, since proteins were still not fully trafficked to the membrane. Unlike wild-type DSC2, the N-terminal mutants were predominantly located in the cytoplasm. Further investigation will be needed to determine whether the mutations could induce "null alleles" potentially leading to haploinsufficiency (i.e. through cytoplasmic degradation) or the mutant proteins could be present in the tissue and act in a dominant fashion (i.e. gain-of-function).
While the involvement of genes encoding desmosomal proteins in ARVC suggests that disruption of desmosomal integrity might be among primary molecular defects [
8], pathogenetic mechanisms leading to ARVC remain to be elucidated. Recent data from Garcia-Gras et al. on cardiac restricted
dsp-deficient mice would point at a novel molecular mechanism through suppression of Wnt/β-catenin signaling by nuclear plakoglobin [
26].
DSC2 mutations were detected in two ARVC probands and in four family members who met only minor diagnostic criteria. This is consistent with incomplete penetrance of the disease, as previously reported in ARVC patients family members carrying
DSP,
PKP2 and
DSG2 mutations [
7,
27‐
29]. However, due to the young age of most of the family members carrying the DSC2 mutations, we cannot exclude that some of them could later show clinical signs of the disease.
None of the probands carrying the pathogenic mutations showed gross skin/hair abnormalities. All DSC isoforms are expressed in the epidermal tissues, whereas DSC2 is the only one expressed in the myocardium. We may hypothesize that compensation by other DSC isoforms might take place in the epidermis but not in the myocardium of DSC2 mutation carriers, thus accounting for the cardiac-specific phenotype.
Conclusion
In conclusion, we identified two novel missense mutations in DSC2 gene associated with ARVC. In vitro functional test demonstrated that N-terminal mutated DSC2 is almost exclusively distributed throughout the cytoplasm, thus suggesting the potential pathogenic effect of the reported mutations.
Identification of additional DSC2 mutations associated with ARVC may result in early detection of asymptomatic carriers and in increased diagnostic accuracy in the clinical evaluation of family members.
Acknowledgements
This study was supported by Telethon grant GGP07220, Rome; National Institutes of Health grant U04HL 65652; ARVC/D project QLG1-CT-2000-01091, Fifth Framework Programme European Commission; Ministry of Health, MIUR and Fondazione Cassa di Risparmio, Padova e Rovigo. The authors are deeply indebted to Paola Marcon for her help in collecting ARVC families, Dr. William Claycomb for providing HL-1 cells and Dr. Alessia Covre for her technical assistance.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
GB performed the mutation screening of DSC2 gene in ARVC patients and carried out the in vitro functional studies. MDB, AL and LS set up DHPLC conditions and performed the mutation screening of DSC2 gene in ARVC patients. AN, BB, CB and GT were in charge of the clinical management of all patients. MS and GL performed the transfection experiments on HL-1 cells. MZ and LM performed transfection experiments on neonatal rat cardiomyocytes. GO designed the PCR primers and conditions used in the mutation screening. JT, head of the NIH project that partially funded our studies, organized the collaborative aspect of the project and provided a critical revision of the paper. GAD contributed to the original design of the study and actively participated in the writing of paper. AR supervised and coordinated the whole project and co-wrote the paper with GB.
All authors read and approved the final manuscript.